The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

Inclusion Criteria

Concurrent Medication:

Allowed:

* Prophylactic pentamidine for Pneumocystis carinii.

Patients must have:

* HIV seropositivity.
* CD4 count \> 50 and \< 200 cells/mm3.
* No active opportunistic infections.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Concurrent neoplasms other than basal cell carcinoma of the skin, in situ carcinoma of the cervix, or Kaposi's sarcoma.
* Significant cardiac disease or CNS lesions or other neurologic abnormalities.
* Score of \> 0.5 on ACTG AIDS Dementia Complex staging.
* Major organ allograft.
* Intolerance to AZT at 500 mg/day.

Concurrent Medication:

Excluded:

* Antihypertensive medication other than diuretics.
* Chemotherapy, hormonal therapy, or other immunotherapy.
* Other investigational drugs, agents, or devices.
* Beta-blockers.
* Non-topical steroids.

Concurrent Treatment:

Excluded:

* Radiation therapy.

Prior Medication:

Excluded:

* Known anti-HIV medication (other than AZT) or known immunomodulators (e.g., systemic steroids, interferons, interleukins) or other chemotherapy within 30 days prior to study entry.

Prior Treatment:

Excluded:

* Transfusion within 4 weeks prior to study entry.
* Radiation within 30 days prior to study entry.

Active substance abuse.